ResMed Inc (RMD)

ResMed is a San Diego-based manufacturer of medical devices and cloud-based software for managing chronic diseases, particularly in respiratory, sleep, and out-of-hospital care settings. Its product portfolio spans hardware (CPAP machines for sleep apnea, ventilators, monitors) and software platforms that allow physicians and hospitals to track patients remotely and adjust treatment in real time. Listed on NASDAQ as RMD, ResMed serves millions of patients globally and is one of the few large medical-devices companies with both hardware and software as equally important profit drivers.

From sleep apnea to a full-spectrum care platform

ResMed was founded in 1989 by a team including Peter Farrell and Geoff Breathwith as a manufacturer of CPAP machines — devices that treat obstructive sleep apnea by gently pressurizing the airway while the patient sleeps. Sleep apnea is a common but often undiagnosed condition affecting tens of millions of people worldwide, particularly in developed countries. Untreated, it raises the risk of heart attack, stroke, and sudden death, making effective treatment important both for patients and for public health.

For decades, CPAP was ResMed’s core business: making machines, selling them to sleep labs and home-care providers, and supporting patients in using them. The company grew steadily, became the market leader in sleep-apnea devices, and expanded into related hardware: masks, tubing, other supplies needed by CPAP users. A patient with newly diagnosed sleep apnea would be sent home with a ResMed machine, and ResMed would benefit from years of supplies, service, and upgrades.

Starting in the 2010s, ResMed began a strategic shift toward software and cloud-based platforms. The company acquired cloud-health companies, built remote-monitoring capabilities, and moved into broader out-of-hospital care — treating patients in their homes, clinics, and provider offices rather than hospitals. By the time of its acquisition by Japan’s Philips Healthcare in 2020 (subsequently divested), ResMed had become as much a software and analytics company as a hardware maker. The company returned to public markets in 2022, with a clearer strategic focus on digital health.

The hardware business: respiratory and monitoring devices

ResMed’s hardware portfolio consists of devices that help patients breathe or allow providers to monitor them. The core categories are:

Sleep and respiratory devices: CPAP machines, bilevel positive airway pressure (BiPAP) machines for patients who cannot tolerate CPAP, and ventilators for hospital and home use. These devices are used by millions of patients nightly and are often prescribed continuously for years, creating sticky customer relationships.

Monitors and sensors: Pulse oximeters, capnography monitors, and other devices that track oxygen levels, carbon dioxide, heart rate, and other vital signs. These are used in hospitals, operating rooms, recovery rooms, and increasingly in home settings.

Portable and transport devices: Compact, battery-powered ventilators and oxygen concentrators for patients who need mobility or those transitioning from hospital to home care.

The hardware business generates revenue in two ways: the capital sale of the machine itself (a one-time or infrequent purchase) and the recurring stream of supplies and services (masks, filters, power cables, software licenses, maintenance contracts). The supplies portion is particularly valuable because a patient who buys a ResMed machine becomes a regular buyer of ResMed mask and filters for years.

Cloud, connectivity, and the software transition

ResMed’s strategic shift toward software reflects a simple insight: knowing that a patient has a device is less valuable than knowing how they are using it and being able to intervene when they are not using it correctly. A patient fitted with a CPAP machine often struggles with adherence — they use it inconsistently, improperly fitted, or abandon it altogether. ResMed’s cloud software collects usage data from the machines (how many hours per night, what pressures were used) and displays it to the patient’s physician or sleep specialist, allowing them to identify problems and coach the patient toward better use.

This model—devices as sensors feeding into a cloud platform that physicians use to manage patients—extends beyond sleep. ResMed has built platforms for hospital respiratory teams to manage ventilators remotely, for clinicians to monitor chronic respiratory diseases like COPD and asthma, and for providers to deliver care to patients at home. The software subscriptions are high-margin, recurring revenue, very different from the hardware business. A hospital might pay annual per-patient or per-device software licenses while also paying for maintenance, integration, and consulting.

ResMed’s acquisition and integration of software and telehealth platforms have positioned the company to offer comprehensive out-of-hospital-care solutions. Care coordination for high-risk patients, chronic-disease management, medication adherence, and provider-to-patient communication are now all within ResMed’s ecosystem.

The fundamental business shift: hardware to software

The strategic tension at ResMed is the gradual shift in revenue mix from hardware to software. Hardware sales are front-loaded and tied to capital purchases; once a hospital or home-care agency has devices, replacement cycles are measured in years. Software subscriptions, by contrast, are recurring and can grow if ResMed can convince customers to adopt more modules and use them more intensively.

ResMed has been explicit about this transition. Management aims to grow software and cloud revenues faster than device revenues, gradually rebalancing the company. This is attractive to investors in high-margin recurring revenue, but it also means the company needs to:

1. Win customer adoption of its software platforms, competing against entrenched hospital IT systems and other digital-health startups.
2. Demonstrate that its software improves patient outcomes or reduces costs enough to justify licensing fees.
3. Integrate acquisitions successfully and retain their customer bases.

Hardware remains important because it is the entry point — a hospital that buys ResMed ventilators is more likely to adopt ResMed’s monitoring and management software — but the story increasingly rests on software traction and cross-selling.

Regulation and reimbursement

Medical devices are heavily regulated. ResMed’s devices must meet regulatory standards (FDA approval in the US, CE mark in Europe, similar requirements in other countries). A major regulatory setback or recall can disrupt product lines and revenue. Additionally, reimbursement — what insurers and government health systems (like Medicare) will pay for devices and software — directly affects demand. If Medicare cuts reimbursement for CPAP machines or out-of-hospital services, ResMed’s revenue falls, as it does for all competitors in those markets.

The global nature of ResMed’s business — it operates in dozens of countries with different healthcare systems and reimbursement policies — means the company is constantly navigating shifting reimbursement landscapes. Strength in one region can mask weakness in another.

Market position and competition

ResMed is the dominant player in sleep apnea devices globally, with a commanding market share. In hospital respiratory and monitoring devices, it competes against Philips (a much larger company), GE Healthcare, Medtronic, and others. In software and cloud platforms, competition is more fragmented and includes both traditional medical-device companies and pure-play digital-health startups.

The sleep-apnea market is mature in developed countries — penetration is high, and growth depends on better diagnosis in emerging markets or new indications. That makes ResMed’s software and out-of-hospital-care initiatives critical to future growth. Expansion in these areas faces stiff competition from established healthcare IT firms and venture-backed digital-health companies.

Understanding ResMed’s trajectory

An investor should begin with the company’s 10-K (SEC CIK 0000943819) to understand the breakdown of revenue by segment (cloud & connected care, respiratory & monitoring, software subscriptions) and to track how the mix is shifting. Watch the margins: software segments are higher-margin than hardware, so a successful mix shift should expand overall operating margins.

Monitor customer acquisition and retention for cloud platforms: is ResMed winning new hospital and clinic customers? Are existing device customers adopting software modules? Look at the rate of acquisition integration — ResMed has made several significant acquisitions, and each one must be successfully integrated to justify the price paid. Finally, stay alert to regulatory changes in key markets, especially Medicare reimbursement policy for out-of-hospital services, and to competitive dynamics in the software market, where new entrants appear frequently and innovation moves fast.